Track record · closed signal

Abbott Laboratories (ABT) — closed signal from January 6, 2026

Partial Published before the outcome was known, scored automatically when the window closed on April 6, 2026.

Predicted vs. what happened

ABT price · publication thesis → realized outcomesplit-adjusted
$128.32 Published $141.15 Target $102.30 Window close $129.46 Peak
$126.00 – $129.00Entry zone — fair-value band
$128.32Published — price the day we called it
$141.15Target — the price the thesis aimed for
$129.46Peak — highest point inside the window, not a realized return
$102.30Window close — end-of-window price, context only

What happened

Partial

Reached 9% of the predicted growth at its peak, without hitting the target.

Peak price
$129.46
peak on January 6, 2026 — not a realized return
Peak gain
+0.9%
peak, from the publication price
Window close
$102.30
end-of-window price, context only
Days to target
—
Window
January 6, 2026 – April 6, 2026

The thesis — published January 6, 2026

Predicted growth
+10%
over the measurement window
Target price
$141.15
the price the thesis aimed for
Entry zone
$126.00 – $129.00
the fair-value band we waited for
Price at publication
$128.32
published January 6, 2026
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Abbott is a steady healthcare company that added an AI feature to its Libre diabetes system, which supports future sales. With earnings coming, investors may adjust positions if management highlights the diabetes business. Expect modest gains; buy small dips rather than chasing big rallies. Watch for a sell-the-news reaction and high expectations.

Primary drivers

  • New AI feature in Libre could help sell more diabetes products
  • Management comments at earnings can change short-term expectations
  • Stable healthcare business helps reduce portfolio ups and downs
  • Buying on dips suits a cautious 0-3 month approach

How it played out

ABT: target was not reached

Lyra published ABT on 2026-01-06 at $128.32 for a short-term window ending 2026-04-06. The thesis expected 10% growth. It pointed to a new artificial intelligence feature in Libre, possible earnings comments on the diabetes business, a stable healthcare base, and a cautious buy-on-dips setup.

Inside the window, ABT peaked at $129.46 on 2026-01-06, a 0.9% gain. It stayed below the $141.15 target and never reached it. By 2026-04-06, it ended at $102.3. The thesis missed.

What happened during the window

On January 22, 2026, Abbott reported fourth-quarter results. An Investors.com article said the stock fell after sales missed expectations and the first-quarter outlook disappointed.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All ABT signals